Abstract
Individuals with elevated LDL-cholesterol levels have an increased risk for cardiovascular disease. Despite lipid lowering strategies, however, a significant cardiovascular risk remains. Bekkering et al. show that monocytes from patients with familial hypercholesterolemia have a trained immunity phenotype and that lipid lowering with statins does not revert this pro-inflammatory phenotype.
Copyright © 2019 Elsevier Inc. All rights reserved.
Publication types
-
Letter
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cardiovascular Diseases / blood
-
Cardiovascular Diseases / drug therapy
-
Cardiovascular Diseases / genetics
-
Cholesterol, LDL / blood
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
-
Hyperlipoproteinemia Type II / blood
-
Hyperlipoproteinemia Type II / drug therapy
-
Hyperlipoproteinemia Type II / genetics
-
Hyperlipoproteinemia Type II / metabolism*
-
Interleukin 1 Receptor Antagonist Protein / blood
-
Interleukin-10 / blood
-
Interleukin-1beta / blood
-
Interleukin-6 / blood
-
Mice
-
Receptors, LDL / blood
Substances
-
Cholesterol, LDL
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1beta
-
Interleukin-6
-
Receptors, LDL
-
Interleukin-10